{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:49:53Z","timestamp":1790250593154,"version":"4.1.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jhep.2015.06.026","type":"journal-article","created":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T12:01:03Z","timestamp":1436097663000},"page":"1238-1253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Optimal management of hepatitis B virus infection \u2013 EASL Special Conference"],"prefix":"10.1016","volume":"63","author":[{"given":"Pietro","family":"Lampertico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.06.026_b0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2015.06.026_b0010","doi-asserted-by":"crossref","first-page":"e44611","DOI":"10.1371\/journal.pone.0044611","article-title":"Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis","volume":"7","author":"Rossi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.06.026_b0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurpub\/cks067","article-title":"Changing epidemiology of hepatitis B and migration\u2014a comparison of six Northern and North-Western European countries","volume":"23","author":"Chu","year":"2013","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.jhep.2015.06.026_b0020","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/liv.12565","article-title":"Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review","volume":"34","author":"Papatheodoridis","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.026_b0025","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(12)62086-8","article-title":"Migration and health in an increasingly diverse Europe","volume":"381","author":"Rechel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.026_b0030","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(13)62291-6","article-title":"Greece\u2019s health crisis: from austerity to denialism","volume":"383","author":"Kentikelenis","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.026_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12120","article-title":"The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference","volume":"20","author":"Hatzakis","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.06.026_b0040","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/jmv.21844","article-title":"Molecular and clinical characteristics of hepatitis B virus in Korea","volume":"82","author":"Ahn","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2015.06.026_b0045","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3851\/IMP1982","article-title":"HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B","volume":"16","author":"Kim","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.06.026_b0050","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.026_b0055","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.05.021","article-title":"Minimization of hepatitis B infection by a 25-year universal vaccination program","volume":"57","author":"Ni","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2334-14-7","article-title":"Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986\u201390) and in the nationwide immunisation program","volume":"14","author":"Peto","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2015.06.026_b0065","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0070","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.jhep.2015.06.026_b0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/JVI.01207-09","article-title":"Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells","volume":"84","author":"Macovei","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.06.026_b0080","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1128\/JVI.00393-13","article-title":"Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment","volume":"87","author":"Macovei","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.06.026_b0085","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2015.06.026_b0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2015.06.026_b0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus","volume":"57","author":"Kramvis","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.jhep.2015.06.026_b0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3851\/IMP1620","article-title":"The host-pathogen interaction during HBV infection: immunological controversies","volume":"15","author":"Bertoletti","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.06.026_b0105","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2015.06.026_b0110","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.79.15.9369-9380.2005","article-title":"Stealth and cunning: hepatitis B and hepatitis C viruses","volume":"79","author":"Wieland","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.06.026_b0115","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.026_b0120","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","article-title":"Temporal analysis of early immune responses in patients with acute hepatitis B virus infection","volume":"137","author":"Dunn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0125","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0130","doi-asserted-by":"crossref","first-page":"e1001227","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","author":"Peppa","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2015.06.026_b0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.20121172","article-title":"Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion","volume":"210","author":"Peppa","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2015.06.026_b0140","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1038\/mtna.2013.43","article-title":"A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus","volume":"2","author":"Koh","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhep.2015.06.026_b0145","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/hep.25875","article-title":"Targeted delivery of interferon-alpha to hepatitis B virus-infected cells using T-cell receptor-like antibodies","volume":"56","author":"Ji","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0150","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ni.2573","article-title":"Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection","volume":"14","author":"Huang","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2015.06.026_b0155","doi-asserted-by":"crossref","first-page":"e1004210","DOI":"10.1371\/journal.ppat.1004210","article-title":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"10","author":"Jo","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2015.06.026_b0160","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0165","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.celrep.2013.02.008","article-title":"Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity","volume":"3","author":"Bottcher","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2015.06.026_b0170","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jhep.2010.12.030","article-title":"Natural history of chronic hepatitis B in Euro-Mediterranean and African countries","volume":"55","author":"Hadziyannis","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0185","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhep.2009.04.003","article-title":"Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia","volume":"51","author":"Liaw","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0190","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.026_b0195","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0210","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0215","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0220","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","article-title":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection","volume":"126","author":"Liaw","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0225","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2014-306977","article-title":"Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers","volume":"64","author":"Tseng","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.026_b0230","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0031-1276642","article-title":"Understanding the host genetics of chronic hepatitis B and C","volume":"31","author":"Thursz","year":"2011","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2015.06.026_b0240","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ng.2483","article-title":"Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma","volume":"45","author":"Jiang","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2015.06.026_b0245","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ng.638","article-title":"Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers","volume":"42","author":"Zhang","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2015.06.026_b0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2350-13-47","article-title":"No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations","volume":"13","author":"Sawai","year":"2012","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jhep.2015.06.026_b0255","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.3748\/wjg.v19.i33.5395","article-title":"HLA class II associated with outcomes of hepatitis B and C infections","volume":"19","author":"Tamori","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.026_b0260","doi-asserted-by":"crossref","first-page":"12176","DOI":"10.1128\/JVI.02073-13","article-title":"HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations","volume":"87","author":"Zhang","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.06.026_b0265","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2010.05.035","article-title":"Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study)","volume":"53","author":"Degos","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0270","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2010.04547.x","article-title":"Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers","volume":"33","author":"Castera","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.026_b0275","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0280","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejca.2011.12.021","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"48","author":"European Association for the Study of the Liver","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2015.06.026_b0285","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12072-010-9165-7","article-title":"Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma","volume":"4","author":"Omata","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.06.026_b0290","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00281-012-0327-7","article-title":"Occult HBV infection","volume":"35","author":"Raimondo","year":"2013","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhep.2015.06.026_b0300","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MOH.0b013e32834bac10","article-title":"Challenges in hepatitis B detection among blood donors","volume":"18","author":"Allain","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jhep.2015.06.026_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2009.01245.x","article-title":"Occult hepatitis B virus infection: a covert operation","volume":"17","author":"Hollinger","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.06.026_b0310","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1007644","article-title":"Nucleic acid testing to detect HBV infection in blood donors","volume":"364","author":"Stramer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.06.026_b0315","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.dld.2012.09.021","article-title":"Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis","volume":"45","author":"Covolo","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.06.026_b0320","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2013.05.043","article-title":"Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C","volume":"59","author":"Squadrito","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0325","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0168-8278(00)80134-8","article-title":"Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation","volume":"33","author":"Blackberg","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0330","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/jhep.2003.50171","article-title":"Long-term histologic and virologic outcomes of acute self-limited hepatitis B","volume":"37","author":"Yuki","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0335","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0340","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0345","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.06.026_b0350","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840050315","article-title":"Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum","volume":"5","author":"Chu","year":"1985","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0355","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0360","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0365","doi-asserted-by":"crossref","first-page":"f4503","DOI":"10.1136\/bmj.f4503","article-title":"The next step in controlling HBV in China","volume":"347","author":"Xu","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2015.06.026_b0370","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2013.08.023","article-title":"Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy","volume":"60","author":"Papatheodoridis","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0375","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?","volume":"58","author":"Thimme","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0380","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0385","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0390","first-page":"9","article-title":"What is the role of cccDNA in chronic HBV infection? Impact on HBV therapy","volume":"4","author":"Petersen","year":"2007","journal-title":"Hepatol Rev"},{"key":"10.1016\/j.jhep.2015.06.026_b0395","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.026_b0400","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.06.026_b0405","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0410","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.06.026_b0415","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2015.06.026_b0420","doi-asserted-by":"crossref","first-page":"e31952","DOI":"10.1371\/journal.pone.0031952","article-title":"Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs","volume":"7","author":"Novellino","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.06.026_b0425","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.06.026_b0430","doi-asserted-by":"crossref","first-page":"e1591","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0435","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0440","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","volume":"56","author":"Murray","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.gastro.2013.11.028","article-title":"Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects","volume":"146","author":"Yapali","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0450","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.3748\/wjg.14.6902","article-title":"Current treatment indications and strategies in chronic hepatitis B virus infection","volume":"14","author":"Papatheodoridis","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.026_b0455","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0460","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jhep.2012.04.029","article-title":"The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis","volume":"57","author":"Kim","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0465","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jhep.2014.02.013","article-title":"Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation","volume":"60","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0470","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1053\/j.gastro.2013.09.031","article-title":"Telbivudine improves renal function in patients with chronic hepatitis B","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0475","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0480","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0485","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0490","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.026_b0495","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.dld.2012.12.013","article-title":"Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B","volume":"45","author":"Bang","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.06.026_b0500","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3109\/00365521.2012.719927","article-title":"Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy","volume":"47","author":"Ko","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.026_b0505","doi-asserted-by":"crossref","first-page":"712","DOI":"10.5009\/gnl.2013.7.6.712","article-title":"Continuous long-term entecavir therapy in naive chronic hepatitis B patients showing partial virologic response","volume":"7","author":"Kwon","year":"2013","journal-title":"Gut Liver"},{"key":"10.1016\/j.jhep.2015.06.026_b0510","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1365-2036.2012.05098.x","article-title":"Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years","volume":"35","author":"Wong","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.026_b0515","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2015.06.026_b0520","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2012.10.016","article-title":"Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes","volume":"58","author":"Burra","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0525","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/lt.23600","article-title":"Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates","volume":"19","author":"Gane","year":"2013","journal-title":"Liver transpl"},{"key":"10.1016\/j.jhep.2015.06.026_b0530","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/lt.23690","article-title":"Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B","volume":"19","author":"Perrillo","year":"2013","journal-title":"Liver transpl"},{"key":"10.1016\/j.jhep.2015.06.026_b0535","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2008.02.064","article-title":"Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation","volume":"134","author":"Faria","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0540","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.3748\/wjg.v18.i34.4677","article-title":"Hepatitis B in pregnancy","volume":"18","author":"Borgia","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.026_b0545","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/infdis\/170.6.1418","article-title":"Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load","volume":"170","author":"Burk","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.06.026_b0550","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2014.04.038","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus","volume":"61","author":"Greenup","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0555","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MEG.0b013e32835f4cbd","article-title":"Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: a meta-analysis","volume":"25","author":"He","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0560","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/cid\/ciu167","article-title":"Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients","volume":"58","author":"Fernandez-Montero","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.06.026_b0565","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.07.005","article-title":"Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study","volume":"59","author":"Manesis","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0570","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/jvh.12251","article-title":"Development and evaluation of a baseline-event-anticipation score for hepatitis delta","volume":"21","author":"Calle Serrano","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.06.026_b0575","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","article-title":"In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus","volume":"112","author":"Bordier","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2015.06.026_b0580","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.026_b0585","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0590","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1440-1746.2008.05384.x","article-title":"Hepatitis B virus\/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment","volume":"23","author":"Chu","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0595","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","article-title":"A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma","volume":"75","author":"Donato","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2015.06.026_b0600","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11901-010-0060-4","article-title":"Current Concepts of HBV\/HCV Coinfection: Coexistence, but Not Necessarily in Harmony","volume":"9","author":"Jamma","year":"2010","journal-title":"Curr Hepat Rep"},{"key":"10.1016\/j.jhep.2015.06.026_b0605","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.22951","article-title":"Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference","volume":"50","author":"Bellecave","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0610","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3851\/IMP2580","article-title":"Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha2a and adefovir","volume":"18","author":"Takkenberg","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.06.026_b0615","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.026_b0620","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2014.08.021","article-title":"Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B was associated with unexpected high rate of peripheral neuropathy","volume":"62","author":"Marcellin","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0625","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1055\/s-0031-1273462","article-title":"Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guidelines","volume":"49","author":"Cornberg","year":"2011","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.026_b0630","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2011.09.018","article-title":"Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study","volume":"56","author":"Petersen","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.026_b0635","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0640","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0645","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime\u2013adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"9","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2015.06.026_b0650","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0655","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2015.06.026_b0660","doi-asserted-by":"crossref","first-page":"e1294","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive methods to assess liver disease in patients with hepatitis B or C","volume":"142","author":"Castera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0665","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/j.gastro.2013.12.036","article-title":"Hepatic immune regulation and its involvement in viral hepatitis infection","volume":"146","author":"Knolle","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.026_b0670","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","article-title":"Hepatitis B viruses: reverse transcription a different way","volume":"134","author":"Nassal","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.jhep.2015.06.026_b0675","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/gutjnl-2012-303291","article-title":"Peginterferon therapy for chronic hepatitis B: one size fits all?","volume":"62","author":"Chan","year":"2013","journal-title":"Gut"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815004535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815004535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:22:38Z","timestamp":1668597758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815004535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0168827815004535"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.06.026","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725620258.793508092","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal management of hepatitis B virus infection \u2013 EASL Special Conference","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}